Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study
The Lancet Respiratory Medicine, 2014•thelancet.com
Background The role of the lung microbiome in the pathogenesis of idiopathic pulmonary
fibrosis is unknown. We investigated whether unique microbial signatures were associated
with progression of idiopathic pulmonary fibrosis. Methods Patients (aged 35–80 years) with
idiopathic pulmonary fibrosis within 4 years of diagnosis from the Correlating Outcomes with
biochemical Markers to Estimate Time-progression (COMET) in idiopathic pulmonary
fibrosis study were followed up for a maximum of 80 weeks. Progression-free survival was …
fibrosis is unknown. We investigated whether unique microbial signatures were associated
with progression of idiopathic pulmonary fibrosis. Methods Patients (aged 35–80 years) with
idiopathic pulmonary fibrosis within 4 years of diagnosis from the Correlating Outcomes with
biochemical Markers to Estimate Time-progression (COMET) in idiopathic pulmonary
fibrosis study were followed up for a maximum of 80 weeks. Progression-free survival was …
Background
The role of the lung microbiome in the pathogenesis of idiopathic pulmonary fibrosis is unknown. We investigated whether unique microbial signatures were associated with progression of idiopathic pulmonary fibrosis.
Methods
Patients (aged 35–80 years) with idiopathic pulmonary fibrosis within 4 years of diagnosis from the Correlating Outcomes with biochemical Markers to Estimate Time-progression (COMET) in idiopathic pulmonary fibrosis study were followed up for a maximum of 80 weeks. Progression-free survival was defined as time to death, acute exacerbation, lung transplant, or decrease in forced vital capacity (FVC) of 10% or greater or decrease in diffusion capacity of the lung (DLCO) of 15% or greater. DNA was isolated from 55 samples of bronchoscopic alveolar lavage. 454 pyrosequencing was used to assign operational taxonomic units (OTUs) to bacteria based on a 3% sequence divergence. Adjusted Cox models were used to identify OTUs that were significantly associated with progression-free survival at a p<0·10. These OTUs were then used in the analysis of the principal components. The association between principal components and microbes with high factor loadings and progression-free survival were assessed with Cox regression analyses. The COMET study is registered with ClinicalTrials.gov, number NCT01071707.
Findings
Mean FVC was 70·1% (SD 17·0) and DLCO 42·3% (14·0) of predicted. Disease progression was significantly associated with increased relative abundance of two OTUs—Streptococcus OTU 1345 (relative risk 1·11, 95% CI 1·04–1·18; p=0·0009) and Staphylococcus OTU 1348 (1·16, 1·03–1·31, p=0·012). Thresholds for relative abundance of each OTU associated with progression-free survival were more than 3·9% for Streptococcus OTU 1345 (10·19, 2·94–35·35; p=0·0002) and more than 1·8% for Staphylococcus OTU 1348 (5·06, 1·71–14·93; p=0·003).
Interpretation
These preliminary data suggest progression of idiopathic pulmonary fibrosis is associated with the presence of specific members within the Staphylococcus and Streptococcus genera. Additional research will be needed to identify the specific bacterial species and to ascertain whether this is a causal association.
Funding
National Institutes of Health.
thelancet.com
